Avifavir® is the first effective drug for COVID‐19 treatment registered in Russia
Benefits in everything
- both in hospitals and at home
- prevention of hospitalization
- faster recovery
- reduced contagiosity and isolated period
- convenient per os
- decreased burden on hospitals by 3 times
- reduced hospitalization period by 30
- reduced disability period
- support of economy
- prevention of lockdown
Avifavir® status by today
A brief history of the development of Avifavir® in the period 2020-2021 Today Avifavir® is registered in 15 countries of the world. The situation changes daily. Avifavir® has entered the international market and the European Medical Alliance is actively involved in this.
Emergency Use Authorization obtaining via fast-track on 60 patients
Avifavir® inclusion in the National Recommendations for the Prevention, Diagnosis and Treatment of New Coronavirus Infection by MOH of Russia
Publication of the Interim Results of a Phase II / III Clinical Trial of Avifavir® in the leading Oxford International Journal (Clinical Infectious Diseases)
Avifavir® inclusion in the Essential drug list by Government of RF Completed Phase III clinical study on 460 patients in 35 centers
Permanent Market Authorization obtaining based on Final Clinical Study Report (Phase III) in Russia
3,000,000+ packages of Avifavir® have been delivered to hospitals in 80 regions of the Russian Federationand abroad AVIFAVIR®. Today Avifavir® is registered in 15 countries.
The entire presentation
Within the shortest term possible, the ChemRar specialists developed testing platforms and a set of methods for the synthesis of substances and pharmaceutical formulation. On May 29th, 2020, after all the pre-clinical and clinical studies were completed, the medicine was registered and became available to patients.We present to your attention the presentation of Avifavir. If necessary, you can download our files and read them in more detail. We have selected all the answers to your questions.
Description in PDF files
For your convenience, you can view the presentation files in any browser without downloading them. To download files to your device, you need to click the arrow in the right corner, enlarge the file and download from our file store.
Acquisition of Avifavir and cooperation with us
We are interested in working with public and private companies to promote Avifavir worldwide.
Read the description of Avifavir in our introductory presentations.
Send us a detailed letter with a presentation of your company to our e-mail, in which you briefly describe your needs for Avifavir, where you plan to deliver the medicine, the country and in what quantities.
We will be sure to read your request and will be sure to answer you. If there is a distributor in your country - we will give his coordinates. If you do not have a distributor in your country, we will describe the steps you need to take to obtain the right to purchase and distribute Avifavir in your country.
We will sign a consultation agreement with you. We will offer you the shortest steps you need to take to get Avifavir delivered or become a distributor in this country. After signing a consulting agreement with us, all negotiations will be conducted with the manufacturer. All contracts will be signed with the manufacturer.
We are professional corporate consultants specializing in healthcare, pharmaceutical and medical technology companies. We analyze markets, plan new product launches and support investment decisions in the CIS and Central Asia.
We work in a team with partners from different countries. Each of us is a professional in his field. In each of our projects, we strive to become a trusted advisor rather than just a requestor. One of our advantages is that most of our clients come back to us and recommend us to other companies.
Our office is located in Pomorie (Bulgaria), which allows us to effectively cover the entire region of Central and Eastern Europe, Central Asia, Africa, Latin America and the CIS. We also provide services all over the world.
We provide consulting services in the following key areas:
Consulting (pre-investment audit, business diagnostics, support of M&A transactions, FCPA audit);
Seminars and trainings (exchange of experience, promotion of innovative achievements in medicine, training of personnel of pharmaceutical companies);
Market access (development of a launch plan, audit of the regulatory environment, market assessment and analysis, prescriber, payer and consumer analysis).